FLINT, Mich., March 14, 2016 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is now filling prescriptions for the Brand-new indication of IMBRUVICA® (ibrutinib). IMBRUVICA® was recently approved by the U.S. Meals and Drug Administration as a first-line treatment for patients along with chronic lymphocytic leukemia (CLL).
To know a lot more concerning Diplomat’s oncology program, click here.
Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.)
CLL is a kind of cancer in which the bone marrow makes also numerous lymphocytes, a kind of white blood cell. CLL is among the many common types of leukemia in adults, accounting for concerning one-quarter of the Brand-new cases of leukemia. According to the American Cancer Society, it is estimated 18,960 individuals will certainly be diagnosed along with CLL in the United States in 2016. The standard age at the moment of diagnosis is about 71 years.
“The approval of IMBRUVICA® as a first-line treatment for patients along with CLL represents an advancement in drug improvement and an necessary option for patients along with this disease,” said Gary Kadlec, Diplomat president.
In February 2014, IMBRUVICA® was approved for the treatment of patients along with CLL that had received a minimum of one prior therapy. IMBRUVICA® is now approved to handle CLL patients regardless of their treatment history (the two treatment-naïve and previously treated patients). In addition, IMBRUVICA® is approved to handle high-risk CLL patients that carry the del 17p, a genetic aberration that occurs as quickly as section of chromosome 17, the location of the tumor suppressor gene p53, has actually been lost or deleted.
Since its launch in 2013, IMBRUVICA® has actually been approved to handle patients with:
- Chronic lymphocytic leukemia (CLL)
- Chronic lymphocytic leukemia (CLL) along with 17p deletion
- Waldenström’s macroglobulinemia (WM)
- Mantle cell lymphoma (MCL) that have actually received a minimum of one prior therapy
IMBRUVICA® is jointly created and commercialized by Pharmacyclics LLC, an AbbVie firm and Janssen Biotech, Inc. Click here for finish IMBRUVICA® prescribing information.
Forward-Looking Statements
This press release contains forward-looking statements gained pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by necessary risks and uncertainties, numerous of which are beyond our control, that could trigger our real outcomes to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you must review Diplomat’s filings along with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed along with or furnished to the Securities and Exchange Commission. Except as could be called for by any sort of applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are gained as of the date hereof or the earlier date explained herein, whether as a result of Brand-new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) serves patients and physicians in every one of 50 states. Headquartered in Flint, Michigan, the firm focuses on medication management solutions for individuals along with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and numerous various other severe or lasting conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy along with one necessary tenet: “Take great care of patients, and the remainder falls in to place.” Today, that tradition continues—constantly focused on enhancing patient care and clinical adherence. For a lot more short article visit www.diplomat.is. Follow us on Twitter and LinkedIn and adore us on Facebook.
CONTACT:
Kali Lucas, Public Relations Coordinator
810.768.9580 | press@diplomat.is
Gary Rice, RPh, MS, MBA, CSP,
Senior Vice President, Clinical Services,
Education and Human Resources
810.768.9863 | grice@diplomat.is
Logo – http://ift.tt/1txIhl3
SOURCE Diplomat Pharmacy, Inc.
